-
Continue reading →: Beyond Nvidia: A New AI Investment FrameworkThe AI investment landscape is evolving. While Nvidia (NVDA) has been the undisputed winner in the AI boom, the market is shifting its focus beyond chipmakers to companies integrating AI into their business models. We need to explore how AI investment strategies are evolving from CapEx spenders vs. receivers to…
-
Continue reading →: Quick thoughts on Amazon’s chip ambitionsAmazon is making a major play in AI hardware with Trainium2, its second-generation AI accelerator designed to compete with Nvidia’s H100 and Google’s TPUv6e. The first version, Trainium1, along with Inferentia2, failed to gain traction for training large AI models due to weak networking and software limitations, leaving AWS heavily…
-
Continue reading →: NVIDIA bearish momentum explained
The market is testing a new narrative for $NVDA. This will be a bull and bear ferocious fight, but the current bear thinking is the following: 1. Overcapacity Risk in Semiconductors: The AI Bubble Narrative Key Issue: Overinvestment Based on Overhyped Demand NVIDIA’s meteoric rise has been fueled by the…
-
Continue reading →: Hermès: A Fantastic BusinessHermès $HESAY is a very interesting brand. It relies solely on craftsmanship and savoir-faire to manufacture its goods. It all boils down to the materials and skills working around those materials, cutting and stitching are more than simple tasks. They are the difference between a bag that costs thousands of…
-
Continue reading →: Magic Touch or Misstep? Reflections on Tapestry $TPRI’ve talked about $TPR before, and I’m sticking to my guns here. They tried to pull off a Louis Vuitton $LVMUY, but let’s be real: it’s not hitting the mark. They brought Stuart Weitzman in 2015 and Kate Spade in 2018 into the fold, thinking they could sprinkle some of…
-
Continue reading →: Invitae’s High-Stakes Financial Maneuvering: Dilution Might Not Be That BadInvitae Corporation (NVTA) faces significant challenges in addressing its liquidity concerns. The firm is exploring multiple strategies to stabilize its financial and operational footing. These strategies encompass potential capital raising, asset divestitures, strategic refocusing on core business and R&D activities, curtailment of capital spending, operating cost reductions, and managing debt…
-
Continue reading →: A primer on the impact of gene therapies and CASGEVY on CRISPR AG and the industryCASGEVY approval CASGEVY is a groundbreaking gene therapy, owned by CRISPR AG (CRSP) and Vertex (VRTX) specifically designed for the treatment of sickle cell disease (SCD) in individuals aged 12 and older who experience frequent vaso-occlusive crises (VOCs). Developed through a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, CASGEVY stands…
-
Continue reading →: China’s Economic Crossroads: Navigating the Delicate BalanceGiven China’s significant role as a key player in the global economy, I maintain a vigilant and analytical approach to Professor Michael Pettis’ insights on its economic strategies. Pettis has long maintained that China’s reliance on supply-side stimulus is a misstep. This is pivotal as China, being the world’s second-largest…
-
Continue reading →: Loose thoughts in a time of uncertaintyAs we navigate the currents of today’s financial markets, we’re witnessing a striking contrast between the resilience of equities and the cautious stance of the bond market. Equity markets, it seems, are choosing to overlook looming challenges, clinging to a narrative of a ‘soft landing’ for the economy. On the…






